NCT00923884CompletedNot Applicable
Prospective Analysis of Genotypes in Adults Undergoing Therapy for Lung Cancer
National Cancer Institute (NCI)1 site in 1 country546 target enrollmentStarted: March 18, 2009Last updated:
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Enrollment
- 546
- Locations
- 1
- Primary Endpoint
- Evaluation of the association between polymorphisms in the enzymes ABCB1, CYP1B1, and CYP19 and clinical outcomes, with overall survival of greatest interest, in patients undergoing treatment for lung cancer.
Study Overview
Brief Summary
Background:
- The Lung Cancer section of the National Cancer Institute s Medical Oncology Branch is running a study to better understand which genes might be important in patients who are undergoing therapy for lung cancer.
Objectives:
- To find out if differences (also called polymorphisms) in specific genes lead to differences in outcomes (such as treatment success and survival rates) for patients who have been diagnosed with lung cancer.
- To establish a repository of genetic information for future studies of these differences and their relation to lung cancer.
Eligibility:
- Any individual who has been diagnosed with lung cancer and is being treated through the National Cancer Institute.
Design:
- After entrance in this study, patients will provide information to the researchers on age, gender, race/ethnicity, treatments received and response to treatments, and other specific information about their disease. This information will be kept confidential.
- Approximately half a tablespoon of blood will be drawn.
- Patients will be treated for lung cancer with normal treatment methods, as if they had not been enrolled in the study
- Some patients may be offered the option of enrolling in separate research protocols for cancer treatment, involving chemotherapy, surgery, or radiation.
Detailed Description
Background:
- Lung cancer is the leading cause of cancer deaths among men and women worldwide.
- Despite modern surgical, radiation, and chemotherapeutic interventions, the prognosis for patients with lung cancer remains poor, with an overall cure rate of less than 15%.
- Genetic polymorphisms in drug-metabolizing enzymes, transporters, growth factor and hormonal receptors, DNA repair enzymes, and transcription factors might affect an individual s response to chemotherapy and radiation.
- Interindividual differences in efficacy and toxicity of cancer chemotherapy and radiation are especially important given the narrow therapeutic index of these modalities.
- Many of these differences have not been extensively explored in patients with lung cancer.
Objectives:
- To better understand the genotype-phenotype relationship between genetic polymorphisms and clinical outcomes, with a focus on overall survival, following lung cancer therapy.
- To better understand differences in outcome between Caucasian and African American patients being treated for lung cancer as a function of genotype.
- To establish a DNA repository for the investigation of polymorphisms related to outcomes in lung cancer.
- To develop methodology for the isolation, enumeration and live cell culture of circulating tumor cells (CTC) from lung cancer patients with microfiltration devices.
Eligibility:
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Prospective
Eligibility Criteria
- Ages
- 18 Years to 100 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Evaluation of the association between polymorphisms in the enzymes ABCB1, CYP1B1, and CYP19 and clinical outcomes, with overall survival of greatest interest, in patients undergoing treatment for lung cancer.
Time Frame: Death or the conclusion of a 5-year follow-up period
Secondary Outcomes
No secondary outcomes reported
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Completed
Not Applicable
Gene Polymorphisms and Symptoms in Lung Cancer PatientsLung CancerNCT00504374M.D. Anderson Cancer Center235
Not yet recruiting
Not Applicable
A Prognosis and Predicting Genetic Study of Lung CancerGenetic Predisposition to DiseaseLung CancerNCT03234179National Taiwan University Hospital500
Recruiting
Not Applicable
Detection of Genetic Markers of Lung CancerLung CancerNCT00280202University of Pittsburgh6,000
Recruiting
Not Applicable
Biomarkers for Risk Stratification in Lung CancerNodule Solitary PulmonaryNon-small Cell Lung CancerNCT03774758University of California, San Francisco590
Recruiting
Not Applicable
Molecular and Genetic Analysis of Lung CancerLung CancerNCT03029325Massachusetts General Hospital15,000